WO2004078995A3 - Methods of modulating and of identifying agents that modulate intracellular calcium - Google Patents

Methods of modulating and of identifying agents that modulate intracellular calcium Download PDF

Info

Publication number
WO2004078995A3
WO2004078995A3 PCT/US2004/006542 US2004006542W WO2004078995A3 WO 2004078995 A3 WO2004078995 A3 WO 2004078995A3 US 2004006542 W US2004006542 W US 2004006542W WO 2004078995 A3 WO2004078995 A3 WO 2004078995A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
modulating
intracellular calcium
identifying agents
modulate intracellular
Prior art date
Application number
PCT/US2004/006542
Other languages
French (fr)
Other versions
WO2004078995A2 (en
Inventor
Jack Roos
Kenneth A Stauderman
Gonul Velicelebi
Kari Lynn Ohlsen
Paul Digregorio
Original Assignee
Neurogenetics Inc
Jack Roos
Kenneth A Stauderman
Gonul Velicelebi
Kari Lynn Ohlsen
Paul Digregorio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogenetics Inc, Jack Roos, Kenneth A Stauderman, Gonul Velicelebi, Kari Lynn Ohlsen, Paul Digregorio filed Critical Neurogenetics Inc
Priority to US10/547,720 priority Critical patent/US7645588B2/en
Publication of WO2004078995A2 publication Critical patent/WO2004078995A2/en
Publication of WO2004078995A3 publication Critical patent/WO2004078995A3/en
Priority to US12/388,791 priority patent/US7820397B2/en
Priority to US12/874,024 priority patent/US8323648B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium.
PCT/US2004/006542 2003-03-04 2004-03-03 Methods of modulating and of identifying agents that modulate intracellular calcium WO2004078995A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/547,720 US7645588B2 (en) 2003-03-04 2004-03-03 Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use
US12/388,791 US7820397B2 (en) 2003-03-04 2009-02-19 Methods of modulating and identifying agents that modulate intracellular calcium
US12/874,024 US8323648B2 (en) 2003-03-04 2010-09-01 Methods of modulating and identifying agents that modulate intracellular calcium

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45195803P 2003-03-04 2003-03-04
US60/451,958 2003-03-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10547720 A-371-Of-International 2004-03-03
US12/388,791 Division US7820397B2 (en) 2003-03-04 2009-02-19 Methods of modulating and identifying agents that modulate intracellular calcium

Publications (2)

Publication Number Publication Date
WO2004078995A2 WO2004078995A2 (en) 2004-09-16
WO2004078995A3 true WO2004078995A3 (en) 2006-10-26

Family

ID=32962670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006542 WO2004078995A2 (en) 2003-03-04 2004-03-03 Methods of modulating and of identifying agents that modulate intracellular calcium

Country Status (2)

Country Link
US (3) US7645588B2 (en)
WO (1) WO2004078995A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730845B (en) * 2007-03-23 2015-04-08 皇后医学中心 Assays and methods for determining stim2 activity

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078995A2 (en) 2003-03-04 2004-09-16 Neurogenetics, Inc. Methods of modulating and of identifying agents that modulate intracellular calcium
WO2005072347A2 (en) * 2004-01-26 2005-08-11 University Of Rochester Inositol 1,4,5- trisphosphate receptor mutants and uses thereof
US7927820B2 (en) * 2004-07-20 2011-04-19 Janssen Pharmaceutica Nv Assay systems and methods for detecting molecules that interact with membrane channels
CA2636417C (en) 2006-01-05 2020-08-25 Immune Disease Institute, Inc. Regulators of nfat
US8431536B2 (en) * 2007-03-05 2013-04-30 The University Of Queensland Target for breast cancer therapy and/or diagnosis
EP2135076B1 (en) 2007-03-23 2016-09-28 The Queen's Medical Center Functional identification of proteins underlying icrac activity in a cell
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
DK2157979T3 (en) 2007-05-24 2018-08-27 Calcimedica Inc CALCIUM CHANNEL PROTEINS AND APPLICATIONS THEREOF
EP2472262A3 (en) 2007-07-10 2012-10-17 Immune Disease Institute, Inc. Stromal interacting molecule knockout mouse and uses thereof
CN101854933A (en) 2007-09-10 2010-10-06 钙医学公司 Regulate the chemical compound of intracellular Ca2+
US20090074750A1 (en) * 2007-09-18 2009-03-19 Onn Brandman Regulator of basal cellular calcium concentration and methods of use
US20110150862A1 (en) * 2008-04-09 2011-06-23 Hulot Jean-Sebastien Inhibitors of stim1 for the treatment of cardiovascular disorders
US8129341B2 (en) * 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
CA2734500A1 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2010099401A1 (en) * 2009-02-26 2010-09-02 The Board Of Trustees Of The Leland Stanford Junior University Calcium signaling modulators involving stim and orai proteins
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010148393A2 (en) * 2009-06-19 2010-12-23 Immune Disease Institute, Inc. Assay for orai calcium channel regulators
US8394778B1 (en) 2009-10-08 2013-03-12 Immune Disease Institute, Inc. Regulators of NFAT and/or store-operated calcium entry
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
WO2011057172A1 (en) * 2009-11-06 2011-05-12 University Of Miami Podocyte specific assays and uses thereof
EP2501407A1 (en) 2009-11-20 2012-09-26 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
ES2591004T3 (en) 2010-04-27 2016-11-24 Calcimedica, Inc. Intracellular calcium modulating compounds
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2582382B1 (en) 2010-06-17 2017-04-19 New York University Cosmetic uses and applications of calreticulin
US9046525B2 (en) * 2010-07-30 2015-06-02 California Institute Of Technology Method of determining the oligomeric state of a protein complex
CN114591311A (en) 2010-08-27 2022-06-07 钙医学公司 Compounds that modulate intracellular calcium
US9567580B2 (en) 2010-10-08 2017-02-14 Anjana Rao Regulators of NFAT and/or store-operated calcium entry
US9540657B2 (en) * 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
HUE056287T2 (en) 2015-02-27 2022-02-28 Calcimedica Inc Pancreatitis treatment
AU2016306301B2 (en) * 2015-08-07 2021-02-11 Calcimedica, Inc. Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury
CN107496420B (en) * 2017-08-25 2020-07-07 中国科学院微生物研究所 Application of cyclopiazonic acid alkaloid compound
CN108179181B (en) * 2017-12-29 2020-12-15 北京泱深生物信息技术有限公司 Application of RDX gene in clinical medication
US20220040162A1 (en) 2018-09-14 2022-02-10 Rhizen Pharmaceuticals Ag Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
EP3714942A1 (en) * 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
EP3714943A1 (en) * 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
CN116261468A (en) 2020-05-20 2023-06-13 钙医学公司 Methods and compositions for treating acute kidney injury
CN117038005B (en) * 2023-10-10 2024-02-20 佛山昊朗药业有限责任公司 Method and device for intelligently adjusting infusion configuration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716150A (en) * 1984-04-05 1987-12-29 Vanderbilt University Synthetic peptides and use thereof in preparing calmodulin antisera
US6171864B1 (en) * 1996-07-05 2001-01-09 Pioneer Hi-Bred International, Inc. Calreticulin genes and promoter regions and uses thereof
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1143013A1 (en) * 2000-04-03 2001-10-10 Warner-Lambert Company Methods and compositions for screening Icrac modulators
WO2002030976A1 (en) 2000-10-11 2002-04-18 The University Of Melbourne Cell control nucleic acids and proteins
WO2004078995A2 (en) 2003-03-04 2004-09-16 Neurogenetics, Inc. Methods of modulating and of identifying agents that modulate intracellular calcium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAMS ET AL.: "Identification and characterization of the STM (stromal interaction molecule) gene family: coding for a novel class of transmembrane proteins", BIOCHEM. J., vol. 357, 2001, pages 673, AND 685 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730845B (en) * 2007-03-23 2015-04-08 皇后医学中心 Assays and methods for determining stim2 activity

Also Published As

Publication number Publication date
US20070031814A1 (en) 2007-02-08
US20090311720A1 (en) 2009-12-17
US20110070237A1 (en) 2011-03-24
WO2004078995A2 (en) 2004-09-16
US7820397B2 (en) 2010-10-26
US8323648B2 (en) 2012-12-04
US7645588B2 (en) 2010-01-12

Similar Documents

Publication Publication Date Title
WO2004078995A3 (en) Methods of modulating and of identifying agents that modulate intracellular calcium
WO2004063362A3 (en) Cell cycle progression proteins
HK1072074A1 (en) Means and methods for the specific modulation of target genes in the eye
EP1501514A4 (en) Protein kinase modulators and methods of use
AU2003219788A1 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1Alpha-
IL165990A0 (en) Methods and compositions for modulating T helper (TH) cell development and function
EP1539931A4 (en) Differentiation modulating agents and uses therefor
IL158750A0 (en) Reagents and methods for modulating dkk-mediated interactions
AU2002309865A1 (en) Methods for analyzing interactions between proteins in live and intact cells
MX2007002277A (en) Methods for making retinoids and uses thereof.
AU2002326980A1 (en) Method of modulating or examining ku70 levels in cells
AU2003252072A1 (en) Modulation of protein kinase c-iota expression
DK1105728T3 (en) Modulation of multiple lineage kinase proteins
AU2003234198A1 (en) Novel genes, compositions, and methods for modulating the unfolded protein response
AU2002256347A1 (en) Compositions and methods for the identification of protein interactions in vertebrate cells
WO2002066954A3 (en) Pdz domain interactions and lipid rafts
WO2005051423A3 (en) Methods and agents for immune modulation and methods for identifying immune modulators
WO2001070776A3 (en) Nimr compositions and their methods of use
EP1628660A4 (en) Methods and compositions for modulating serum cortisol levels
AU2002339904A1 (en) Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
WO2003087051A3 (en) Methods for identifying allosteric sites
AU2002255881A1 (en) Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use
WO2005055942A3 (en) Modulation of brain pathways and function
AU2002364612A1 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
AU2003304490A1 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 2007031814

Country of ref document: US

Ref document number: 10547720

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10547720

Country of ref document: US